The first oral medication to treat postpartum depression (PPD) in adults was historically approved by the FDA. PPD is a type of depression that typically appears after childbirth or as early as the final trimester of pregnancy.
Postpartum Depression
Like other forms of depression, PPD is a serious and potentially life-threatening condition to women and their child(ren). In addition to common depressive experience like extreme sadness and worthlessness, PPD can influence suicidal or homicidal thoughts on women and their child(ren). Even in “moderate levels” it can compromise the maternal-infant bond and subsequently impair the child’s emotional development.
Postpartum depression effects 1 in 7 women nationally and unfortunately Black women are less likely to receive treatment for PPD. Zurzuva (zuranolone) holds the potential to address racial disparities in care. It is a 14-day, single daily pill treatment that has demonstrated a significant improvement in depressive symptoms in two randomized, double-blind, placebo-controlled, multicenter studies. Due to its rapid effects and two-week treatment duration, the pill could potentially promote greater engagement in addressing this debilitating condition compared to other antidepressants.
Words to meet the text length. Length text required more words. Still need more comments. This is so hard. I probably need a new paragraph.